Earnings Summary

Bellicum Pharmaceuticals Inc’s revenue jumped NaN% since last year same period to $0Mn in the Q2 2023. On a quarterly growth basis, Bellicum Pharmaceuticals Inc has generated -100% fall in its revenue since last 3-months.

Bellicum Pharmaceuticals Inc’s net profit fell -83.75% since last year same period to $-7.35Mn in the Q2 2023. On a quarterly growth basis, Bellicum Pharmaceuticals Inc has generated 1.8% jump in its net profits since last 3-months.

Bellicum Pharmaceuticals Inc’s net profit margin jumped NaN% since last year same period to -Inf% in the Q2 2023. On a quarterly growth basis, Bellicum Pharmaceuticals Inc has generated -Inf% fall in its net profit margins since last 3-months.

Bellicum Pharmaceuticals Inc’s earning per share (EPS) estimates for the current quarter stand at -0.93 - a -45.31% fall from last quarter’s estimates.

Bellicum Pharmaceuticals Inc’s earning per share (EPS) estimates for the current year stand at -0.93.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Bellicum Pharmaceuticals Inc’s return on assets (ROA) stands at -0.83.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Bellicum Pharmaceuticals Inc’s return on equity (ROE) stands at -1.54.